Suchergebnisse - "Fishbane, Steven"

PubPharm (19)

1

Introduction : Iron Management in Chronic Kidney Disease

enthalten in: Seminars in nephrology | 2016

von Fishbane, S.

2

The emerging role of biosimilar epoetins in nephrology in the United States

enthalten in: American journal of kidney diseases : the official journal of the National Kidney Foundation | 2015

von Fishbane, S. | Shah, H.

3

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients? : The use of iron supplementation to reduce ESA dosing in hemodialysis

enthalten in: Seminars in dialysis | 2013

von Shirazian, S. | Grant, C. | Miller, I. | +1

4

Anemia management in chronic kidney disease

enthalten in: Kidney international. Supplement | 2010

von Fishbane, S. | Nissenson, A.

5

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure

enthalten in: Kidney international | 2010

von Fishbane, S. | Miyawaki, N.

CommentOn: Kidney Int. 2010 Feb;77(3):239-46. - PMID 19890274

6

Managing anemia in dialysis patients : hemoglobin cycling and overshoot

enthalten in: Kidney international | 2008

von Singh, A. | Milford, E. | Fishbane, S. | +1

7

Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients

enthalten in: Clinical journal of the American Society of Nephrology : CJASN | 2008

von Kilpatrick, R. | Critchlow, C. | Fishbane, S. | +4

CommentIn: Clin J Am Soc Nephrol. 2008 Jul;3(4):935-7. - PMID 18579671

8

Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration

enthalten in: Journal of clinical pharmacology | 2007

von Fishbane, S. | Pannier, A. | Liogier, X. | +3

9

Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis : a randomised non-inferiority trial (MAXIMA)

enthalten in: Lancet (London, England) | 2007

von Levin, N. | Fishbane, S. | Cañedo, F. | +7

ErratumIn: Lancet. 2008 Feb 2;371(9610):386

10

Efficacy and tolerability of intravenous continuous erythropoietin receptor activator : a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease

enthalten in: Clinical therapeutics | 2007

von Besarab, A. | Salifu, M. | Lunde, N. | +5